Spironolactone
- Generic Name
- Spironolactone
- Brand Names
- Aldactazide, Aldactone, Carospir, Qaialdo
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4S
- CAS Number
- 52-01-7
- Unique Ingredient Identifier
- 27O7W4T232
- Background
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several ...
- Indication
Spironolactone is indicated for the treatment of the following conditions:
As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.
- Associated Conditions
- Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
- Associated Therapies
- Perioperative drug treatment, Maintenance therapy
Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Svendborg Hospital
- Target Recruit Count
- 125
- Registration Number
- NCT02764619
- Locations
- 🇩🇰
Department of Cardiovascular Research, Medical Department, Odense University Hospital, Svendborg, Svendborg, Region of Southern Denmark, Denmark
Spironolactone in Atrial Fibrillation
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 250
- Registration Number
- NCT02673463
- Locations
- 🇬🇧
University of Birmingham Institute of Cardiovascular Sciences, Birmingham, West Midlands, United Kingdom
Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Actinium Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT02575963
- Locations
- 🇺🇸
University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸Columbia University Medical, Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸St. Francis Cancer Center, Greenville, South Carolina, United States
Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer Patients
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Instituto Nacional de Cancerologia de Mexico
- Target Recruit Count
- 24
- Registration Number
- NCT02531412
- Locations
- 🇲🇽
Nacional Cancer Institute, Mexico, Distrito Federal, Mexico
Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD
- Conditions
- Interventions
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- University Hospital Birmingham
- Target Recruit Count
- 154
- Registration Number
- NCT02502981
- Locations
- 🇬🇧
Royal Free Hospital, London, United Kingdom
🇬🇧Departments of Cardiology & Nephrology University Hospital Birmingham, Birmingham, West Midlands, United Kingdom
🇬🇧University of Edinburgh: BHF Centre for Cardiovascular Science and Western General Hospital, Edinburgh, United Kingdom
Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 21
- Registration Number
- NCT02497300
- Locations
- 🇺🇸
Hypertension Research Clinic at UAB, Birmingham, Alabama, United States
High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure
- Locations
- 🇺🇸
University Hospital, San Antonio, Texas, United States
Short Term Spironolactone for Prevention of Acute Kidney Injury After Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
- Target Recruit Count
- 150
- Registration Number
- NCT02417896
- Locations
- 🇲🇽
Instituto Nacional de la Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico
🇲🇽Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Distrito Federal, Mexico
European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- University Hospital Goettingen
- Target Recruit Count
- 500
- Registration Number
- NCT02378805
- Locations
- 🇩🇪
University Hospital Goettingen, Goettingen, Germany
Optimum Treatment for Drug-Resistant Hypertension
- Conditions
- Interventions
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- University of Cambridge
- Target Recruit Count
- 348
- Registration Number
- NCT02369081
- Locations
- 🇬🇧
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧University of Birmingham, Birmingham, United Kingdom
🇬🇧University of Cambridge - Addenbrookes Hospital, Cambridge, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.